Taking advantage of the use of dogs in preclinical therapeutic studies, our findings may open up interesting opportunities to validate the role of CD24 as a therapeutic target for prostate cancer and further investigate how CD24 overexpression may be related to tumor features that may be useful for a specific prognostic or predictive approach. This evidence concerns the gene CD24 and Familial prostate cancer.